Korean Government Boosts KOSDAQ Biotech Sector with Strategic Support
The Korean government has unveiled comprehensive KOSDAQ support measures that are reigniting investor interest in the biotech sector. The National Pension Service plans to increase KOSDAQ allocation from 3% to approximately 5%, while venture fund priority allocations will expand from 25% to over 30%.
Most significantly, the 150 trillion won National Growth Fund will actively support KOSDAQ revitalization, with biotechnology designated as one of the top 10 strategic industries alongside AI and semiconductors. As interest rate cuts materialize, biotech emerges as an essential investment sector within KOSDAQ’s representative industries.
Two Critical Conditions for Biotech Sector Leadership
The second half of 2024 established clear conditions for biotech to become a leading sector:
Condition 1: Major Global Technology Transfer Deals
- Platform companies (Alteogen, ABL Bio, LegoChem Biosciences) or biotech firms with market caps exceeding 1 trillion won securing Big Pharma contracts
Condition 2: December Interest Rate Cuts
- Federal Reserve rate cut probability rising to 85%, now confirmed
Both conditions are now fulfilled. ABL Bio signed a 3.8 trillion won ($2.85B) blood-brain barrier (BBB) shuttle platform technology transfer with Eli Lilly, including strategic equity investment.
Korean Biotech Companies Partnering with Eli Lilly
Multiple Korean companies have secured deals with Eli Lilly, the world’s #1 pharmaceutical company by market cap:
| Company | Deal Size | Technology | Status |
|---|---|---|---|
| Rznomics | 1.9 trillion won ($1.4B) | RNA Editing Platform | IPO: December 18, 2025 |
| Ollix | Undisclosed | Nucleic Acid Therapeutics | Listed |
| ABL Bio | 3.8 trillion won ($2.85B) | BBB Shuttle Platform | Listed |
This demonstrates structural growth in Korea’s biotech industry. Technology transfer agreements with global pharmaceutical companies are expected to accelerate.
Rznomics: Pioneering RNA Editing Platform Technology
Rznomics, preparing for KOSDAQ listing on December 18, 2025, is Korea’s only RNA editing platform company. Globally, only a handful of companies have advanced RNA multi-editing drug platforms to clinical stages.
The Economic Moat: RNA Platform Technology
https://youtu.be/5CGdOacxwaE?si=DUwxxje0hGLIwxKV
How Rznomics’ RNA Substitution Enzyme Platform Works
- Precisely cuts pathogenic RNA
- Replaces with therapeutic RNA to generate new RNA
- Self-editing system using ribozymes
Advantages Over CRISPR Technology
| Feature | CRISPR | RzNomics RNA Platform |
|---|---|---|
| Action Level | Direct DNA (genome) editing | RNA-level intervention |
| Toxicity Risk | Insertion mutations possible | Lower genotoxicity risk |
| Editing Tool | Requires external proteins | Self-contained ribozymes |
| Stability | Relatively lower | Superior |
The platform eliminates external protein editors, reducing cellular protein conflicts and enhancing stability.
Eli Lilly’s $1.4B Deal: Strategic Significance
The May 2025 platform technology transfer agreement with Eli Lilly totals 1.96 trillion won ($1.4B), targeting hereditary hearing loss treatments. Upfront payments exceed 7 billion won ($5.3M) per candidate molecule.
Hereditary Hearing Loss Market Potential
Hereditary hearing loss typically involves multiple genes and mutations. Multi-target, multi-gene editing platforms are essential—single gene correction is insufficient. Rznomics’ RNA splicing platform can modify entire “sentences” rather than single “letters,” making it ideal for this application.
Eli Lilly acquired Akouos in 2022 to enter the hereditary hearing loss market. With no established treatments available, they selected Rznomics’ platform to capture this untapped market.
Deal Structure Highlights
The contract structure strongly favors Rznomics:
- R&D Funding: Eli Lilly covers joint research and early development costs
- Cost Reduction: Development expenses significantly offset during candidate molecule development
- Long-term Revenue: Secures technical POC, shared development costs, and long-term royalties
Industry experts consider this an ideal platform business deal structure.
Next Target: Alzheimer’s Disease Treatment
RzNomics’ next technology transfer opportunity centers on Alzheimer’s disease—a massive unmet need in aging societies that every global pharmaceutical company wants to solve.
APOE4 Targeting Strategy
Between 40-65% of Alzheimer’s patients express the APOE4 protein. APOE4 carriers face 3-12x higher disease risk compared to the general population.
RzNomics’ Approach:
- Ribozymes recognize and cut pathogenic APOE4 RNA
- Replace with therapeutic RNA (functioning like protective APOE2/3)
- Generate new chimeric RNA
- Reduce APOE4 protein expression in brain + increase protective gene expression
Current Alzheimer’s treatments are either symptom-management drugs or amyloid-beta-based therapies (lecanemab, donanemab) with significant side effect concerns. RzNomics presents a novel approach addressing the disease’s root cause, with in vivo imaging data demonstrating successful gene expression regulation in the brain.
US Biotech Sector Trends and Investment Outlook
The XBI (SPDR S&P Biotech ETF), representing US biotech, continues reaching new highs, while the NASDAQ Biotechnology Index trends upward. Both Big Pharma and biotech companies are outperforming, with M&A activity accelerating.
Benefits of Biotech Investing During Rate Cut Cycles:
- Growth stock valuation improvements
- Enhanced biotech fundraising environment
- Active M&A creating premium valuations
Structural Growth in Korean Biotechnology
Korean biotech companies increasingly secure favorable deal structures with global pharmaceutical firms—beyond simple technology provision to platform value recognition, with R&D cost sharing and long-term royalty arrangements.
Investment Focus Points:
- Monitor Platform Big 3: Alteogen, ABL Bio, LegoChem Biosciences
- Track global technology transfer agreements
- Verify clinical trial progress and data
- Watch RzNomics December IPO
Conclusion: Biotech Sector Investment Timing
Three simultaneous catalysts are converging: (1) KOSDAQ support policies, (2) confirmed interest rate cuts, and (3) major Big Pharma contracts. Rznomics’ KOSDAQ listing will further validate Korean biotech industry capabilities.
RNA therapeutics represent next-generation biotech’s core technology, with Rznomics leading this field. The company demonstrates sustained growth potential, expanding from hereditary hearing loss to Alzheimer’s disease indications.
Investor Note: This article is for informational purposes only and does not constitute investment advice. Always conduct thorough due diligence and consult financial professionals before making investment decisions.